Navigation Links
Advances in Surgical Technologies Boost Demand for Efficient Bone Graft Substitutes, Finds Frost & Sullivan
Date:3/27/2013

MOUNTAIN VIEW, Calif., March 27, 2013 /PRNewswire/ -- Product and technology improvements in healthcare increased the number of orthopedic surgeries and subsequently, the demand for efficacious bone graft materials in the United States. Owing to these technology introductions, new market segments such as cell-based matrices are gaining at the expense of some others, such as the bone morphogenetic protein (BMP) market.

New analysis from Frost & Sullivan's (http://www.medtech.frost.com) Analysis of the United States Bone Grafts and Bone Graft Substitutes Market research finds the market earned revenue of $1.60 billion in 2012 and estimates this to reach $1.65 billion in 2016.

For more information on this research, please email Britni Myers , Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

A significant percent of the orthopedic patient population is comprised of baby boomers that lead active lifestyles and are prone to injuries. The younger demographic patient pool is also expanding, as minimally invasive surgery techniques enable partial joint replacement surgeries.

"Despite these market opportunities, companies are differentiating themselves on the cost effectiveness of their products due to the current economic scenario," said Frost & Sullivan Advanced Medical Technologies Senior Industry Analyst Aarti Shetty . "With comparative effectiveness programs in place, the newer biologics technologies will be compared with existing, proven methods."

Major orthopedic surgeries are established procedures and reimbursements are not an issue. However, with innovation, the prices for bone graft products have started escalating, making cost-benefit analyses crucial for reimbursement.

Poor or lack of reimbursement for expensive innovative technologies hinders technology adoption. The newer technologies in all segments have limited clinical data that supports their advantages over autografts. Thus, obtaining approval for reimbursement for products with minimal cost-benefit analyses is becoming increasingly difficult.

"Differentiation based on unique functions and patient outcomes in the bone graft substitutes market is becoming a vital competitive factor, especially with the entry of more competitors," noted Shetty. "The introduction of new product segments with strong clinical data will give a significant boost to investors' interest in the bone grafts and bone graft substitutes market."

Analysis of the United States Bone Grafts and Bone Graft Substitutes Market is part of the Advanced Medical Technologies Growth Partnership Service program, which also includes: Analysis of the Hip Implants Market, Analysis of the Knee Implants Market, Analysis of the Orthopedic Implants Market – The Future of Joint Replacements, and U.S. Tissue Engineering Markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Analysis of the United States Bone Grafts and Bone Graft Substitutes Market
NB90-54

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
2. Northridge Dentists, Dr. Ariz and Dr. Arami, Use Latest Technological Advances in Dentistry
3. West Health Institute demonstrates research advances in medical device interoperability to lower the cost of health care
4. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
5. MedInformatix RIS Advances Carolina Regional Radiologys Progress in Meeting Meaningful Use Objectives
6. GlaxoSmithKline advances multi-city discussion focused on improving the health of US communities
7. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
8. Advances in Delivery to the Central Nervous System
9. Accelrys ELN Advances Innovation Lifecycle Management with Enhanced Biology Capabilities from Screening to Preclinical Development
10. Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
11. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/24/2017)... -- ITL Limited, ( ASX : ITD ), une société ... les excellents résultats semestriels clos le 31 décembre 2016 ... complète « Résultats et mise à jour sur la croissance ... Faits marquants ... en hausse de 104 %) Bénéfice par ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):